2.
Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor
by Im, Hyungsoon
Nature biotechnology, 2014, Vol.32 (5), p.490-495
3.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, ad...
by Finn, Richard S, MD
The lancet oncology, 2015, Vol.16 (1), p.25-35
4.
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
by Cimino-Mathews, Ashley, MD
Human pathology, 2015, Vol.47 (1), p.52-63
5.
Mining the plasma proteome for cancer biomarkers
by Hanash, Samir M
Nature, 2008, Vol.452 (7187), p.571-579
6.
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, place...
by Tabernero, Josep
The lancet oncology, 2018, Vol.19 (10), p.1372-1384
7.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
by Baselga, José, Dr
The Lancet (British edition), 2012, Vol.379 (9816), p.633-640
8.
Enabling personalized cancer medicine through analysis of gene-expression patterns
by van 't Veer, Laura J
Nature, 2008, Vol.452 (7187), p.564-570
9.
Tumor budding in colorectal cancer—ready for diagnostic practice?
by Koelzer, Viktor H., MD
Human pathology, 2015, Vol.47 (1), p.4-19
10.
Updated UK Recommendations for HER2 assessment in breast cancer
by Rakha, Emad A
Journal of clinical pathology, 2015, Vol.68 (2), p.93-99
11.
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
by Weichert, Wilko, Dr
The lancet oncology, 2008, Vol.9 (2), p.139-148
12.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof
The Lancet (British edition), 2017, Vol.389 (10075), p.1195-1205
13.
PD-L1 expression as a potential predictive biomarker
by Fusi, Alberto
The lancet oncology, 2015, Vol.16 (13), p.1285-1287
14.
Prognostic significance of PD-L1 and PD-L2 in breast cancer
by Baptista, Mauricio Z., MD, PhD
Human pathology, 2015, Vol.47 (1), p.78-84
15.
Evaluation of the diagnostic and prognostic value of PDL1-expression in Hodgkin- and B-cell lymphomas
by Menter, Thomas
Human pathology, 2016, Vol.54, p.17-24
16.
17.
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
by Hiley, Crispin T, MD
The Lancet (British edition), 2016, Vol.388 (10048), p.1002-1011
18.
Non-small-cell lung cancer
by Goldstraw, Peter, Prof
The Lancet (British edition), 2011, Vol.378 (9804), p.1727-1740
19.
MicroRNAs accurately identify cancer tissue origin
by Aharonov, Ranit
Nature biotechnology, 2008, Vol.26 (4), p.462-469
20.
Colorectal cancer
by Cunningham, David, Prof
The Lancet (British edition), 2010, Vol.375 (9719), p.1030-1047
